Compare QBTS & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QBTS | KRYS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | 388 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.6B |
| IPO Year | N/A | 2017 |
| Metric | QBTS | KRYS |
|---|---|---|
| Price | $24.27 | $345.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $32.53 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 39.7M | 242.1K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $81.05 | $38.74 |
| Revenue Next Year | $93.13 | $32.53 |
| P/E Ratio | ★ N/A | $186.02 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $12.75 | $130.17 |
| 52 Week High | $46.75 | $347.67 |
| Indicator | QBTS | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 73.08 |
| Support Level | $23.20 | $253.89 |
| Resistance Level | $24.78 | N/A |
| Average True Range (ATR) | 2.40 | 12.58 |
| MACD | -0.54 | 3.13 |
| Stochastic Oscillator | 20.00 | 86.78 |
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.